Uvax Bio Appoints Kevin O’Neill as Interim Chief Executive Officer

Uvax Bio Appoints Kevin O’Neill as Interim Chief Executive Officer

NEWARK, Del., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Uvax Bio, LLC, (“Uvax” or “the Company”) a privately held, clinical-stage vaccine company utilizing...

Uvax Bio Appoints Kevin O’Neill as Interim CEO

NEWARK, DE — Uvax Bio, LLC has announced the appointment of Kevin O’Neill as Interim Chief Executive Officer (CEO), succeeding company co-founder Ji Li, Ph.D. The leadership transition comes as the company advances its innovative vaccine development programs targeting a range of challenging diseases. “The Board welcomes Kevin and is confident he will continue to champion our technology and vaccines while maintaining a focus on our various develo…